Precigen (PGEN) Secures FDA Platform Status For AdenoVerse And Future Therapies
Precigen (PGEN) has announced that its AdenoVerse immunotherapeutic platform has been granted platform technology designation by the FDA. This designation allows data and review learnings from one product to support future product candidates built on the same backbone, potentially accelerating the development of multiple therapies for various conditions, including HPV-positive cancers. This move is seen as addressing pipeline diversification, providing a clearer regulatory path for AdenoVerse programs by leveraging existing PAPZIMEOS data and manufacturing.
B. Riley Securities initiates coverage of Precigen with Buy rating, $12 price target
B. Riley Securities has initiated coverage on Precigen (PGEN) with a Buy rating and a $12 price target, indicating a 55.8% upside from its previous close. The positive outlook is driven by Precigen's strong clinical pipeline, particularly PRGN-2009 for HPV-associated cancers, and its valuable proprietary technology platforms like AdenoVerse immunotherapy and UltraCAR-T. The firm projects significant revenue growth for the company through 2035.
Precigen stock hits 52-week high at 8.05 USD
Precigen Inc.'s stock reached a 52-week high of $8.05, currently trading at $8.10 with a market capitalization of $2.76 billion, reflecting a significant 119.37% increase over the past year. This strong performance follows robust second-quarter results, where the company surpassed analyst expectations due to strong demand for its FDA-approved therapy, PAPZIMEOS, and a "buy" rating initiation from B.Riley with a $12 price target. Despite analysts anticipating sales growth, InvestingPro suggests the stock may be overvalued at its current levels.
Precigen Initiated at Buy by B. Riley Securities
B. Riley Securities has initiated coverage on Precigen (PGEN) with a Buy rating. This indicates a positive outlook from the firm regarding Precigen's stock performance.
Is Precigen (PGEN) Above Fair Value After The FDA Platform Nod?
Precigen (PGEN) has seen significant stock gains recently, raising questions about its valuation relative to its sales and pipeline, especially after receiving FDA platform technology designation for its AdenoVerse immunotherapeutic platform. Despite this, the company's P/S ratio of 32.2x is considerably higher than the biotech industry and peer averages, indicating that its current price may be above its fair value according to various financial models. The article suggests that investors need to weigh whether current sales and product pipeline justify such a steep revenue multiple.
$Precigen (PGEN.US)$ ready for the next leg higher
The article, posted by user Papacito, suggests that Precigen (PGEN.US) is poised for an upward movement in its stock price. It is a brief statement within a financial community platform, with no further analytical details provided in the body of the text.
Can PGEN's AdenoVerse Pipeline Create Growth Beyond Papzimeos?
Precigen (PGEN) is aiming to expand its growth beyond its successful Papzimeos franchise through its AdenoVerse platform. The company is developing PRGN-2009 for HPV-driven cancers, which recently received FDA platform technology designation, potentially opening doors for future candidates. While Papzimeos continues to drive significant revenue, Precigen hopes the AdenoVerse pipeline, particularly PRGN-2009, will provide long-term growth opportunities and complement its existing commercial success.
How FDA Platform Status Will Impact Precigen Stock Investors
Precigen received FDA platform technology designation for its AdenoVerse immunotherapeutic platform, which is expected to streamline future development by reusing manufacturing and preclinical knowledge. This designation supports the investment narrative for Precigen (PGEN), particularly benefiting programs like PRGN 2009 in Phase 2 trials, by allowing management to focus more on clinical execution and potentially diversifying the company beyond its single approved indication, PAPZIMEOS. However, the company faces risks including its cash runway and current loss-making status, making execution on PRGN 2009 progress critical for future growth and justifying its high P/S multiple.
FDA grants platform technology status to Precigen’s AdenoVerse
The FDA has granted platform technology designation to Precigen Inc.'s AdenoVerse immunotherapeutic platform, which was previously approved for treating recurrent respiratory papillomatosis. This designation allows Precigen to use existing data and manufacturing knowledge for future therapies targeting HPV-positive malignancies, facilitating earlier engagement with the FDA. Precigen is a biopharmaceutical company focusing on immuno-oncology, autoimmune disorders, and infectious diseases.
September 2026's Leading Growth Companies With Insider Backing
This article identifies top growth companies in the United States with high insider ownership, highlighting their potential for appealing investment. It details three specific companies: BillionToOne (BLLN), Precigen (PGEN), and Daqo New Energy (DQ), providing an overview of their operations, insider ownership, and earnings growth forecasts. The piece suggests that high insider ownership indicates confidence from those closest to the company's operations, making these companies attractive in a growing market.
Precigen (PGEN) Receives FDA Platform Technology Designation for AdenoVerse
Precigen (PGEN) announced that the FDA has granted Platform Technology Designation for its AdenoVerse platform. This regulatory recognition is an early-stage milestone that could streamline development and de-risk pipeline perception for multiple candidates built on the platform. While positive, a larger catalyst would involve specific trial advancements or clearances that lead to revenue visibility.
Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform
Precigen, Inc. announced that its AdenoVerse immunotherapeutic platform, used in its FDA-approved product PAPZIMEOS, has received Platform Technology Designation from the FDA. This designation allows Precigen to leverage existing data and manufacturing knowledge to potentially accelerate the development of future AdenoVerse-based therapies, including PRGN-2009 for HPV-associated cancers. It provides opportunities for earlier and more frequent FDA engagement, aiming to reduce duplicative work and increase efficiency in developing new treatments.
A treatment platform could help speed future drugs, Precigen says
Precigen (PGEN) has received FDA platform technology designation for its AdenoVerse immunotherapeutic platform, which is already used in its approved product PAPZIMEOS. This designation acknowledges the platform's adaptability and potential to accelerate the development, manufacturing, and regulatory review of future AdenoVerse-based programs. The company expects this will significantly benefit its ongoing Phase 2 trials for HPV-associated cancers and other future candidates by allowing it to leverage existing data and engage more frequently with the FDA.
Precigen stock hits 52-week high at 7.74 USD By Investing.com
Precigen Inc.'s stock recently hit a 52-week high of $7.74, currently trading at $7.83, reflecting strong market performance with a 110% gain over six months and 78% year-to-date. This biotechnology firm's stock has appreciated by 95.66% over the past year, driven by investor confidence and its innovative gene and cell therapy approaches. Despite being considered overvalued and not profitable in the last twelve months, analysts predict profitability for the company this year, further bolstered by its strong Q2 2026 financial results which saw earnings surpass forecasts significantly due to strong demand for PAPZIMEOS.
Precigen stock hits 52-week high at 7.74 USD
Precigen's stock has reached a new 52-week high of $7.74 USD, with its current price at $7.83, reflecting significant gains over six months (110%) and year-to-date (78%). The biotechnology firm's strong market performance and investor confidence are supported by impressive Q2 2026 financial results, which showed a swing to profitability with earnings of $0.05 per share and revenue of $54.98 million, largely due to demand for its PAPZIMEOS therapy. While InvestingPro analysis indicates the stock is currently overvalued, analysts predict profitability for the company this year.
Precigen Gains 43% in 3 Months: Is It an Indication to Buy the Stock?
Precigen (PGEN) has seen a 42.7% stock rally in the past three months, driven by the strong commercial performance of its FDA-approved drug, Papzimeos, for recurrent respiratory papillomatosis (RRP). The company is also making progress with its AdenoVerse platform and other pipeline candidates, such as PRGN-2009 for HPV-driven cancers. Despite a premium valuation, the strong commercial momentum, pipeline potential, and improving earnings estimates have led to a "Strong Buy" recommendation from Zacks Investment Research.
Q3 2025 Precigen Inc Earnings Call Transcript
This article provides the Q3 2025 earnings call transcript for Precigen Inc (PGEN), highlighting the full FDA approval and successful U.S. launch of Papsius for recurrent respiratory papillomatosis (RRP). Key positive points include Papsius's high complete response rate and reduction in surgical burden, along with plans for international expansion. Negative aspects discussed include the lack of specific revenue guidance, reimbursement challenges, increased SG&A costs, and market competition.
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen
The biotechnology industry has shown resilience this year due to strong quarterly results, new drug approvals, and positive clinical developments, despite economic uncertainties. Mergers and acquisitions are also boosting the sector, with large companies acquiring smaller innovative biotechs. Zacks highlights Halozyme, Repligen, Iovance, Arcutis, and Precigen as five biotech stocks poised for strong performance.
Precigen COO Rutul Shah sells $375,000 in shares
Precigen's COO, Rutul R. Shah, sold 50,000 shares of the company's stock in two transactions in late August 2026, totaling approximately $375,000. These sales occurred after Shah acquired shares through stock option exercises and RSU settlements, with the stock trading near its 52-week high. The company recently reported strong Q2 results, exceeding revenue and earnings expectations, largely due to demand for its PAPZIMEOS therapy.
Precigen CCO Phil Tennant sells $593,745 in stock
Precigen's Chief Commercial Officer, Phil Tennant, sold 79,166 shares of company stock for $593,745. This sale occurred while the stock was trading near its 52-week high after an 83% gain over the past year. The transaction was made according to a pre-arranged 10b5-1 trading plan and followed his acquisition of shares through RSU settlements and option exercises.
Precigen (NASDAQ: PGEN) CFO settles RSUs, withholds 3,577 shares for taxes
Precigen's (NASDAQ: PGEN) CFO, Harry Thomasian Jr., settled 7,291 Restricted Stock Units (RSUs) on August 23, 2026, which converted into common stock. To cover income tax withholding obligations, 3,577 shares were withheld at a value of $7.20 per share, categorized as a code F disposition. Following these transactions, Thomasian Jr. directly holds 80,209 RSUs, with no open market purchases or sales reported.
Precigen (PGEN) COO unloads 50K shares at $7.50 under plan
Precigen's (PGEN) Chief Operating Officer, Rutul R. Shah, exercised stock options and RSUs and subsequently sold 50,000 common shares at $7.50 per share through a Rule 10b5-1 trading plan. The transactions occurred on August 21 and 25, 2026, following the exercise of options at $2.33 per share. Additionally, 7,500 RSUs converted to common stock on August 23, 2026, with some shares withheld for tax obligations.
Precigen (PGEN) insider lines up another stock sale after four recent trades
Precigen (PGEN) officer Rutul Shah plans to sell 15,342 common shares valued at approximately $115,065.00 through Fidelity Brokerage Services LLC on or after August 25, 2026, following a stock option exercise. This proposed sale comes after four previous sales of Precigen common shares by the same individual within the prior three months, totaling over $950,000. The transaction was disclosed via a Form 144 SEC filing.
Precigen (NASDAQ: PGEN) officer to sell 79,166 shares in 2026
An officer at Precigen (NASDAQ: PGEN), Phillip Tennant, has filed a Rule 144 notice to sell up to 79,166 shares of common stock. The sale, valued at an aggregate market value of $593,745.00, is planned for on or after August 25, 2026, through Fidelity Brokerage Services LLC. These shares are associated with a stock option exercise.
Precigen Insider Sold Shares Worth $375,000, According to a Recent SEC Filing
An insider at Precigen, Inc. (PGEN) sold shares valued at $375,000, as disclosed in a recent SEC filing. This transaction follows several other insider share sales for the company in recent months. Precigen is a biopharmaceutical company focused on developing gene and cell therapies in immuno-oncology, autoimmune disorders, and infectious diseases.
Precigen Q2 Results: Profitability returns as PAPZIMEOS revenue doubles
Precigen (NASDAQ: PGEN) achieved profitability in Q2 2026, driven by a doubling of net product revenue from its FDA-approved therapy, PAPZIMEOS, to $53.1 million. The company is also advancing PRGN-2009 for HPV-driven cancers, with Phase 2 trials underway and head and neck data expected in Q4. This commercial success validates Precigen's AdenoVerse platform, allowing for manageable fixed costs and the expansion of its therapeutic pipeline.
PGEN Looks 52.5% Undervalued on GF Value™ Despite Profitability Challenges
Precigen Inc (PGEN) achieved profitability in Q2 2026 with net product revenue from PAPZIMEOS surpassing $53 million, yet faces ongoing profitability and financial strength challenges. Despite a high Price-to-Sales ratio suggesting strong future growth, its GF Score™ of 53/100 indicates moderate growth potential but weak financial health. While GuruFocus's GF Value™ estimates the stock as 52.5% undervalued, significant insider selling and a "Possible Value Trap" warning advise caution for investors.
Precigen's Strong Second Quarter Signals Significant Growth, Validates AdenoVerse Platform; PRGN-2009 Advances in HPV-Driven Cancers
Precigen Inc. reported strong commercial traction in its second quarter, with its product PAPILOMAVEC generating $35.1 million in net product revenue. The company's AdenoVerse platform has demonstrated its ability to target HPV-associated diseases, with PRGN-2009 advancing in HPV-driven cancers through ongoing Phase 2 trials. This commercial success and the platform's potential in oncology mark a significant step for Precigen.
Precigen's Strong Second Quarter Signals Significant Growth, Validates AdenoVerse Platform; PRGN-2009 Advances in HPV-Driven Cancers
Precigen Inc. reported a strong second quarter, with its drug PAPZIMEOS generating $53.1 million in net product revenue, validating the company's AdenoVerse platform. This success allows for the advancement of PRGN-2009, which uses the same platform to target high-risk oncogenic HPV types in various cancers, currently in Phase 2 trials. The company aims to leverage the commercial success of PAPZIMEOS to expand the AdenoVerse platform's potential into the larger oncology market.
Precigen's Strong Second Quarter Signals Significant Growth, Validates AdenoVerse Platform; PRGN-2009 Advances in HPV-Driven Cancers
Precigen Inc. (NASDAQ: PGEN) reported a strong second quarter, with PAPZIMEOS generating over $53 million in revenue, leading to quarterly profitability and validating its AdenoVerse platform. The company is advancing PRGN-2009, which uses the same platform, into Phase 2 trials for HPV-driven cancers, building on promising Phase 1 results. This commercial success and pipeline progression indicate significant growth potential for the AdenoVerse platform in a larger oncology market.
Precigen (PGEN) officer targets $259,935 insider stock sale
Precigen (PGEN) officer Rutul Shah has filed a Rule 144 notice to sell up to 34,658 shares of common stock, valued at approximately $259,935, following a stock option exercise on or after August 21, 2026. This proposed sale will be executed through Fidelity Brokerage Services LLC. The filing also details three prior common stock sales by Rutul Shah within the last three months, totaling over 109,000 shares.
$Precigen (PGEN.US)$ keep it up!
The article is a short, positive message about Precigen (PGEN.US) posted on the moomoo community platform. A user named "Papacito" encourages the stock to continue performing well, expressing optimism for its future trajectory. The post includes general disclaimers about the community platform being for educational purposes.
3 Growth Companies With High Insider Ownership And 55% Earnings Growth
This article identifies three growth companies—Corcept Therapeutics (CORT), BillionToOne (BLLN), and Precigen (PGEN)—that exhibit high insider ownership and strong earnings growth potential, despite recent market fluctuations. It highlights that high insider ownership often signals confidence in a company's future, making these firms attractive to investors looking for growth opportunities. Each company's financial overview, insider ownership, and earnings forecasts are detailed, with Precigen showing particularly high projected earnings growth.
Precigen (NASDAQ:PGEN) Trading Down 3.6% - Here's Why
Precigen (NASDAQ:PGEN) shares fell 3.6% in midday trading on Friday, despite generally positive analyst sentiment and strong quarterly earnings that exceeded expectations. The stock's decline comes amid significant insider selling, with nearly 989,000 shares worth $5.47 million sold over the past 90 days. Institutional investors have shown mixed activity, with some increasing stakes and others initiating new positions in the biotechnology company.
3 Growth Companies With High Insider Ownership And 55% Earnings Growth
This article highlights three U.S. growth companies—Corcept Therapeutics, BillionToOne, and Precigen—that exhibit high insider ownership and strong earnings growth forecasts. Despite a recent market drop, these companies are presented as potential opportunities due to their internal confidence and robust financial outlooks. Each company's overview, insider ownership, and earnings growth projections are detailed, along with recent developments.
$Precigen (PGEN.US)$ keep it up!
A moomoo community user, Papacito, posted a short message expressing optimism for Precigen (PGEN.US) with the phrase "keep it up!" The post garnered 602 views and included a comment from the same user anticipating the stock to continue rising.
Precigen to Announce Second Quarter 2026 Financial Results and Provide Business Updates on August 4
Precigen, Inc. (Nasdaq: PGEN) announced that it will release its second quarter 2026 financial results and provide business updates on Tuesday, August 4, 2026. The biopharmaceutical company will also host a conference call on the same day at 4:30 PM ET to discuss the results. Investors and interested parties can find event details on the company's website.
Precigen stock hits 52-week high at 7.33 USD By Investing.com
Precigen Inc (PGEN) has reached a new 52-week high of $7.33, demonstrating strong performance with a 1-year change of 100.27% and a 123% actual one-year price total return. The company's stock has doubled, reflecting investor confidence and recent advancements, including a strong second-quarter performance with earnings surpassing expectations and revenue nearly doubling forecasts, primarily due to demand for its PAPZIMEOS therapy.
Precigen stock hits 52-week high at 7.33 USD
Precigen (PGEN) has reached a new 52-week high of $7.33, reflecting strong investor confidence with a 1-year change of 100.27% and a year-to-date gain of 71%. The biotechnology company reported robust Q2 performance, surpassing analyst expectations for earnings and revenue, largely due to strong demand for its therapy PAPZIMEOS. InvestingPro data indicates impressive returns across multiple timeframes and suggests the stock is currently trading at fair value.
Stock Traders Buy Large Volume of Precigen Call Options (NASDAQ:PGEN)
Precigen (NASDAQ: PGEN) experienced a significant surge in call option activity, with investors acquiring 31,516 call options, representing a 704% increase over the average volume. This unusual trading volume indicates strong speculative interest in the biotechnology company. While analysts generally hold a "Moderate Buy" rating with a target price of $14.50, insiders have sold a considerable amount of shares, contrasting with institutional investors like Patient Capital Management and BlackRock, who have built significant positions.
Alpine Woods Capital Investors LLC Takes $1.31 Million Position in Precigen, Inc. $PGEN
Alpine Woods Capital Investors LLC has acquired a new position in Precigen, Inc. (NASDAQ:PGEN), purchasing 229,618 shares valued at approximately $1.31 million. This investment comes as Precigen reported strong Q2 earnings, with revenue up 6,322.7% year-over-year and beating analyst estimates. Despite mixed analyst sentiment, with an average "Moderate Buy" rating, company insiders have recently sold nearly 1 million shares.
$Precigen (PGEN.US)$ DCA'd Up. Ready for the next leg higher
The author, Papacito, discusses dollar-cost averaging into Precigen (PGEN.US) and expresses readiness for the stock's next upward movement. This brief post is part of a community discussion on moomoo, highlighting a personal investment strategy.
Precigen Inc. (PGEN) Stock Price | Live Quotes & Charts | NASDAQ
This page provides live quotes and charts for Precigen Inc. (PGEN) stock on NASDAQ, showing a current price of $6.72 with a 2.60% increase. It indicates that there is no analyst rating or earnings information available for the company at this time. The page also features educational content related to stock trading and investing, particularly focusing on penny stocks.
Precigen (NASDAQ:PGEN) Trading Down 5.5% - What's Next?
Precigen (NASDAQ:PGEN) saw its shares drop by 5.5% despite reporting stronger-than-expected quarterly results, with EPS of $0.05 against an estimated loss of $0.01, and revenue soaring by 6,322.7% year-over-year to $54.98 million. The biotechnology company maintains a "Moderate Buy" consensus rating with an average price target of $14.50. Insider selling has occurred recently, totaling nearly $5.47 million over the past 90 days, though insiders still hold a significant 41.4% ownership stake.
Precigen (PGEN) Q2 2026 Earnings Call Transcript
Precigen (PGEN) reported its first-ever quarterly net profit in Q2 2026, driven by significant revenue growth for its lead therapy, PAPZIMEOS. The company saw a 145.8% increase in net revenue to $53.1 million, with high gross margins and broad payer coverage. Precigen anticipates continued growth and expects to reach cash flow breakeven by the end of 2026, while also advancing its clinical pipeline, including the PRGN-2009 program for HPV-related cancers.
Precigen (PGEN) Is Up 16.3% After Papsimios-Fueled Return To Profitability And Broad Payer Coverage
Precigen (PGEN) reported a significant financial turnaround in Q2 2026, achieving profitability with $54.98 million in revenue and $20.07 million in net income, driven by the strong uptake of its drug Papsimios. This success is supported by broad payer coverage for 315 million US lives and a seven-year FDA market exclusivity for adult recurrent respiratory papillomatosis. While this strengthens Precigen's near-term outlook, the company's long-term growth and liquidity still depend on sustained demand for Papsimios and managing its fixed costs.
Precigen (PGEN) Insider Rutul Shah Sells 32,739 Shares
Precigen (PGEN) insider Rutul Shah sold 32,739 shares of the company on August 6, 2026, totaling approximately $224,589. This transaction is part of a larger pattern where insiders have sold significantly more shares than they purchased over the past year. Despite the stock trading at a substantial discount to its GF Value, GuruFocus has labeled it a "Possible Value Trap," advising caution due to potential underlying concerns.
COO sale: Precigen (PGEN) insider trades 32,739 shares via plan
Precigen's Chief Operating Officer, Rutul R Shah, sold 32,739 shares of common stock at $6.86 per share on August 6, 2026, through a Rule 10b5-1 trading plan. Following this transaction, Shah directly holds 465,012 shares. The sale amounted to approximately $225,000, and the filing indicates it was an open-market or private transaction.
PRECIGEN, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $18 FROM $14
H.C. Wainwright has raised its target price for Precigen, Inc. to $18, an increase from its previous target of $14. This update indicates a more optimistic outlook from the analyst firm regarding the company's future stock performance.
Results: Precigen, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
The article discusses how Precigen, Inc. exceeded expectations, leading analysts to update their financial estimates for the company. This suggests a positive outlook for Precigen's future performance based on recent results.
